While past FDA chiefs have joined drugmaker boards following their tenure, Gottlieb's move to Pfizer is both rapid and more high-profile than that of past...
Despite spending billions on R&D, big pharma doesn't punch its weight in discovering the new molecules that eventually make it to market.
Instead, it's often...
While BioMarin and Spark remain out in front, Sangamo's data appear strong enough to warrant consideration of the biotech's therapy in the discussion of...
While Bristol-Myers executives successfully beat back Starboard and Wellington's efforts to derail the deal, the questions raised by that opposition remain.
By buying Celgene, Bristol-Myers...
Intra-Cellular's success and failure demonstrate the difficulty of developing psychiatric drugs. Unqualified clinical success in depression is particularly challenging, as high placebo responses can...
Expectations for Evenity (romosozumab) are modest, and the rejection by the EMA is a "minor setback" for Amgen, according to RBC Capital Markets analyst...
Brain cancers are among the most difficult to treat, as Tocagen's struggles follow late-stage study failures earlier this month from AbbVie and Bristol-Myers Squibb.
The...
Four months after Morphic reached an R&D deal with AbbVie, the Waltham, Massachusetts-based biotech has found another drugmaking giant to partner with.
Morphic and AbbVie...
While BioMarin and Spark remain out in front, Sangamo's data appear strong enough to warrant consideration of the biotech's therapy in the discussion of...
MacroGenics stock took a beating Tuesday, dropping far more than any other biotech on the iShares NASDAQ Biotechnology Index as the ASCO conference closed....
The administration faces increasing pressure to release a concrete healthcare plan as Democratic presidential candidates are eager to keep the national conversation focused...
Novo is best known for its insulin products like Levemir (insulin detemir) and Tresiba (insulin degludec), as well as other diabetes treatments like...
